Regarding this excellent interview on Al Jazeera of Dr. NP

New Post Public Reply Private Reply Replies (3) Message Board
blafarm
815
Regarding this excellent interview on Al Jazeera of Dr. NP which was posted just yesterday:

Video Link: https://www.youtube.com/watch?v=iBHRTf9Q7eA

There are a couple of "big ticket" topics that I have not heard anyone raise:

Video Link = https://youtu.be/iBHRTf9Q7eA?t=156
Quote:
"We are now close to asking the FDA to approve the drug for compassionate use for everybody who is in severe condition because our mechanism of action which will be publishing a paper hopefully by the end of this week or so"
My Comments:

1. Other than CytoDyn's (assumed) failed attempt to gain FDA approval based upon the relatively small, non-control, EIND program, I don't remember any previous statement by Dr. NP regarding asking the FDA for approval of the drug for compassionate use.

Does anyone else remember this?

Is this a preview of what might be discussed on Monday?



2. At the very end of the Friday, April 17 conference call, while discussing his research paper, Dr. BP indicated that all of the data would finally be available in one week (that was yesterday), and that the paper would be submitted in two weeks (next Friday), and that it would not be published for 4-6 weeks (between May 8 and May 21). And, I noted in a post around that time that the release of paper would coincide nicely with the read-out of 2-week preliminary results. In this Al Jazeera interview, Dr. NP is stating: "... we will be publishing a paper hopefully by the end of this week."

My Comments:

Am I assigning too much significance to this remark?

Does anyone think the paper will be publicly circulated prior to being officially published between May 8 and May 21, according to Dr. BP?


3. Video Link: https://youtu.be/iBHRTf9Q7eA?t=188
Quote:
Correspondent: “So if the FDA gives you final approval would that also apply to other countries would it be good enough for the European Union or other countries to go ahead and start using the medication?

Dr. NP: “So each country has their own rules and regulation. United Kingdom has asked us already for the product to be involved in this test that we have they have indicated that the European Food and Drug Administration is agreeing to allow this product to be used in any clinical trial as long as the FDA in United States agrees to allow the clinical trials to go forward and have a green light. We have green light not for Phase 2 but also for one Phase 3 the final pivotal trial we believe and the other countries also always they follow the guidelines of FDA United States and the European Food and Drug Administration. So if both of these are aligned then the rest of the world would also immediately would allow us to be used for this special problem."
My Comments:

I have no idea what to make of Dr. NP's response. Can anyone interpret this for me -- in a clear and concise manner that allows me to understand/predict if we may hear that the UK has approved emergency use of leronlimab, as was discussed in that same April 17th conference call?

4. Video Link: https://youtu.be/iBHRTf9Q7eA?t=326
Quote:
In United States we have Bill Gates Foundation, NIH National Institute of Health Foundation reserve fundings we have
Quote:
amfAR that has funding, Barda has funding -- so all these funds that could be used to disperse this product without any cost to the third-world countries is going to be at work immediately. I have been approached already by a couple those institutions and they are saying that your science look very strong, your results look strong, if we if it happens that you get approval which could happen in the next perhaps six to eight weeks even, if those best-case scenario happen can we be involved to immediately have this product available for third world country? And we said absolutely yes. They asked us for the cost of the product. The cost is very minimum it's not very large and it's we are able to cover the whole world. We have our manufacturing at Samsung biologic in South Korea said where they could produce tremendous amount of product. And we have manufacturing United States ready to go. Everything set we need the FDA approval and we needed to have some proof of concept. Things are going very well with the patients who have received this product in Emergency IMD and reported it. But the trial is double-blinded we don't know the results for another two or three weeks and then we will know what path we have to take.
My Comments:

I like that Dr. NP has stated he has "been approached already by a couple those institutions". I think we had all hoped/assumed that had taken place (due to the strength of the drug's efficacy) -- but now we have clear evidence.

I also like his comment "The cost is very minimum it's not very large and it's we are able to cover the whole world." I like that he is going on record as being able to scale production and distribution (my words) to the entire world.

Regarding pricing, we all know the cost issue is a double edged sword. In the context of a pandemic , the company's reputation would be permanently damaged if CytoDyn pulled a "Martin Shkreli" and price-gouged the entire world.

This is an incredibly important inflection point for the company, and it must exit this pandemic looking like the hero that saved the world -- and that saved the world like the other big pharma companies promised to do -- effectively for free.

However, when this is over, and CytoDyn moves forward to monetize leronlimab for other indications, I anticipate some blow-back regarding pricing. I can see the headlines: "Company that saved the world is now overcharging for their drug."

I also anticipate an overhang in inventory, with potentially millions of unused vials sitting all over the planet -- at the point that a vaccine is available.

Whether or not those vials will have expired (as suggested by another board member), whether or not an expired vial still has any effectiveness, and whether or not doctors around the world will inject their patients suffering from other diseases with those vials -- all remains to be seen.

However, we have to assume that by the time a vaccine is ready, and those vials are no longer necessary, we will have had FDA approval for Combo HIV, and maybe even a label extension for Mono HIV. And who knows how much progress will have been made, or how many BTD's we might have acquired, for other cancer and immuno indications.

In other words, the temptation to use those vials, in both 1st world and especially in 3rd world countries, might be very strong. And that glut of inventory will certainly have an impact on demand and revenue.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 87

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 108

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
First Time Homebuyer Tips for Southern Maryland Success

Updated Category News Views 94

Shaking Up First-Time Homebuyer Assumptions Ever hear that age-old nonsense about needing a fat stack of cash as a down payment before you can snag your first home? Yeah, turns out that's about as outdated as a rotary phone. Robin Cavallaro from RE/MAX Realty Group in Annapolis is setting the record straight for first-time buyers in Southern Maryland. Down Payment Myths...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 70

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 188

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 77

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Smart Mattress Market Expected to Reach USD 2.3 Billion Soon

Updated Category News Views 231

Overview of the Smart Mattress Market Growth Smart mattresses have emerged as key players in the bedding industry, shaped by the rising awareness of sleep's importance to overall health. With a current valuation of approximately USD 1.6 billion in 2023, the market is projected to reach USD 2.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.7% in the...

Continue Reading
VyStar Foundation Celebrates Investment in Kennesaw State Education

Updated Category News Views 178

VyStar Credit Union and Kennesaw State Unveil VyStar Arena The anticipation surrounding the recent unveiling of VyStar Arena at Kennesaw State University is palpable, marking a significant achievement for both the university and VyStar Credit Union. This newly renovated arena will serve as the heart of athletic activities, hosting women's volleyball and men's basketball...

Continue Reading
Google Cloud and Verizon Transform Customer Engagement with AI

Updated Category News Views 599

Google Cloud and Verizon: Pioneering Customer Experience Innovations In a groundbreaking collaboration, Google Cloud has joined forces with Verizon to revolutionize customer service through innovative technology. This partnership leverages Google Cloud's generative AI to enhance the way Verizon serves its customers, resulting in significant improvements in customer...

Continue Reading
Celebrating the Holidays: Joyful Activities for Seniors

Updated Category News Views 161

Bringing Festive Cheer to Seniors This Holiday Season The holiday season is a special time for celebration, togetherness, and creating lasting memories, particularly for our seniors. Executive Home Care is dedicated to enhancing the holiday spirit for seniors by encouraging families and caregivers to engage in joyful activities that uplift and connect the loved ones in...

Continue Reading
Paragon Sports Revolution: NYC Store's Bold Overhaul

Updated Category News Views 32

Paragon Sports Redefines NYC's Retail Scene If you're thinking classic old guard can't innovate, take a gander at Paragon Sports. This 118-year-old New York cornerstone isn't just resting on its laurels as some ancient relic; they're breaking out the playbook for a fresh start in the Big Apple. In a bold move, they’ve decided to not only enhance their in-store...

Continue Reading